{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:08:13Z","timestamp":1782756493097,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.therap.2023.06.004","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T14:37:22Z","timestamp":1686839842000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Augmentation des surdoses et d\u00e9c\u00e8s en lien avec la consommation de m\u00e9thadone durant la crise sanitaire li\u00e9e au COVID-19\u00a0en 2020"],"prefix":"10.1016","volume":"79","author":[{"given":"Elisabeth","family":"Frauger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fouilh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynald","family":"Le Boisselier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lian","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Revol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gibaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Aquizerate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chaouachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.06.004_bib0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.therap.2018.09.070","article-title":"Am\u00e9liorer la balance b\u00e9n\u00e9fices\/risques de la m\u00e9thadone en respectant ses sp\u00e9cificit\u00e9s pharmacologiques","volume":"74","author":"Frauger","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.06.004_bib0150","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Arr\u00eat\u00e9 du 19\u00a0mars2020\u00a0compl\u00e9tant l\u2019arr\u00eat\u00e9 du 14\u00a0mars 2020\u00a0portant diversesmesures relatives \u00e0 la lutte contre la propagation du virus COVID-19. JORF 2020. https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000041737443&categorieLien=id. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19\u00a0epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.06.004_bib0160","unstructured":"ANSM. Pharmacovigilance et addictovigilance dans le contexte du COVID-19: une surveillance renforc\u00e9e. 2020. https:\/\/www.ansm.sante.fr\/Declarer-un-effet-indesirable\/Systemes-de-vigilances-de-l-Agence\/COVID-19-Dispositif-renforce-de-Pharmacovigilance-et-d-Addictovigilance\/(offset)\/0. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0165","unstructured":"Centre d\u2019addictovigilance de Marseille. Rapport d\u2019addictovigilance sur l\u2019\u00e9valuation et la synth\u00e8se des signalements marquants en p\u00e9riode COVID (SIMAD COVID). Rapport. Aout 2020. https:\/\/addictovigilance.fr\/wp-content\/uploads\/2022\/05\/20201008-covid-rapport-simad-covid.pdf. [Consult\u00e9 le 13\u00a0juin 2023 (10\u00a0pp.)]."},{"key":"10.1016\/j.therap.2023.06.004_bib0170","unstructured":"Centre d\u2019addictovigilance de Marseille et Centre d\u2019addictovigilance de Grenoble. Rapport d\u2019addictovigilance sur les tendances actuelles des surdosages en lien avec la consommation de m\u00e9thadone en 2020\u00a0au regard des tendances observ\u00e9es en 2019 (sur le 1er semestre de chaque ann\u00e9e). Rapport. Octobre 2020. https:\/\/addictovigilance.fr\/wp-content\/uploads\/2022\/05\/20201008-covid-rapport-tendances-surdosages-methadone.pdf. [Consult\u00e9 le 13\u00a0juin 2023 (30\u00a0pp.)]."},{"key":"10.1016\/j.therap.2023.06.004_bib0175","unstructured":"Centre d\u2019addictovigilance de Marseille et Centre d\u2019addictovigilance de Grenoble. Rapport d\u2019addictovigilance sur les tendances actuelles des surdosages en lien avec la consommation de m\u00e9thadone en 2020\u00a0au regard des tendances observ\u00e9es en 2019 (sur l\u2019ann\u00e9e). Rapport. Pr\u00e9ent\u00e9 au CSP de juin 2021. Mai 2021. https:\/\/ansm.sante.fr\/uploads\/2021\/10\/20\/cr-csp-psa-2021-06-10.pdf. [Consult\u00e9 le 13\u00a0juin 2023 (13\u00a0pp.)]."},{"key":"10.1016\/j.therap.2023.06.004_bib0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.therap.2022.06.003","article-title":"Hospitalisations apr\u00e8s consommation de substances psychoactives pendant la pand\u00e9mie de COVID-19","volume":"78","author":"Dumoulin","year":"2023","journal-title":"Therapie"},{"issue":"S1","key":"10.1016\/j.therap.2023.06.004_bib0185","first-page":"37","article-title":"Impact of lockdown in COVID-19\u00a0on methadone-use related hospitalizations in France","volume":"36","author":"Demourgues","year":"2022","journal-title":"Fundamental Clinical Pharmacology"},{"key":"10.1016\/j.therap.2023.06.004_bib0190","doi-asserted-by":"crossref","first-page":"103877","DOI":"10.1016\/j.drugpo.2022.103877","article-title":"Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19\u00a0pandemic in England","volume":"110","author":"Aldabergenov","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2023.06.004_bib0195","doi-asserted-by":"crossref","first-page":"109703","DOI":"10.1016\/j.drugalcdep.2022.109703","article-title":"Methadone-involved overdose deaths in the United States before and during the COVID-19\u00a0pandemic","volume":"242","author":"Kleinman","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2023.06.004_bib0200","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2023.06.004_bib0205","doi-asserted-by":"crossref","first-page":"111579","DOI":"10.1016\/j.forsciint.2023.111579","article-title":"Examination of methadone involved overdoses during the COVID-19\u00a0pandemic","volume":"344","author":"Kaufman","year":"2023","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2023.06.004_bib0210","doi-asserted-by":"crossref","first-page":"103591","DOI":"10.1016\/j.drugpo.2022.103591","article-title":"Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations","volume":"102","author":"Welsh","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2023.06.004_bib0215","doi-asserted-by":"crossref","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19","volume":"131","author":"Brothers","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2023.06.004_bib0220","doi-asserted-by":"crossref","first-page":"e2118223","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19\u00a0pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2023.06.004_bib0225","doi-asserted-by":"crossref","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths \u2014 United States, 2002-2014","volume":"65","author":"Jones","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.therap.2023.06.004_bib0230","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Comit\u00e9 scientifique permanent psychotropes, stup\u00e9fiants et addictions - Juin 2021. 2021. https:\/\/ansm.sante.fr\/evenements\/comite-psychotropes-stupefiants-et-addictions-6. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0235","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9. Comit\u00e9 scientifique permanent psychotropes, stup\u00e9fiants et addictions - octobre 2021. 2021. https:\/\/ansm.sante.fr\/evenements\/comite-psychotropes-stupefiants-et-addictions-7. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0240","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on problems of drug dependence clinical practice guideline","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"key":"10.1016\/j.therap.2023.06.004_bib0245","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10550887.2011.610710","article-title":"QT Interval screening in methadone maintenance treatment: report of a SAMHSA expert panel","volume":"30","author":"Martin","year":"2011","journal-title":"J Addict Dis"},{"key":"10.1016\/j.therap.2023.06.004_bib0250","unstructured":"Association des centres d\u2019addictovigilance. Communiqu\u00e9 \u00ab\u00a0M\u00e9thadone et confinement li\u00e9 au COVID-19\u00a0: assurer la continuit\u00e9 du traitement tout en maintenant la s\u00e9curit\u00e9 de son usage\u00a0\u00bb (diffusion le 14\u00a0avril 2020). 2020. https:\/\/addictovigilance.fr\/2020\/06\/communique-de-lassociation-francaise-des-centres-daddictovigilance-methadone-et-confinement-lie-au-covid-19-assurer-la-continuite-du-traitement-tout-en-maintenant-la-securite-de\/. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0255","unstructured":"Association des centres d\u2019addictovigilance. Plaquette \u00ab\u00a0Int\u00e9r\u00eat d\u2019une diffusion large de Naloxone\u00a0\u00bb (diffusion le 14\u00a0avril 2020). 2020. https:\/\/addictovigilance.fr\/2020\/06\/communique-de-lassociation-francaise-des-centres-daddictovigilance-methadone-et-confinement-lie-au-covid-19-assurer-la-continuite-du-traitement-tout-en-maintenant-la-securite-de\/. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0260","unstructured":"Association des centres d\u2019addictovigilance. Plaquette destin\u00e9e au patient \u00ab\u00a0Soyons plus que jamais vigilants avec la M\u00e9thadone\u00a0\u00bb (diffusion le 08\u00a0juin 2020). 2020. https:\/\/addictovigilance.fr\/2020\/06\/communique-de-lassociation-francaise-des-centres-daddictovigilance-methadone-et-confinement-lie-au-covid-19-assurer-la-continuite-du-traitement-tout-en-maintenant-la-securite-de\/. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0265","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Site d\u2019information public sur les m\u00e9dicaments. 2023. https:\/\/sfpt-fr.org\/covid19-foire-aux-questions. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0270","unstructured":"ANSM. Point d\u2019information\u00a0: L\u2019ANSM rappelle les risques de la m\u00e9thadone et l\u2019importance de disposer de la naloxone - Point d\u2019information (diffus\u00e9 le 16\u00a0juillet 2020). 2020. https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/L-ANSM-rappelle-les-risques-de-la-methadone-et-l-importance-de-disposer-de-la-naloxone-Point-d-information. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0275","unstructured":"Ministre des solidarit\u00e9s et de la sant\u00e9. Surdoses (overdose) d\u2019opio\u00efdes\u00a0: la naloxone est utilisable par tous et peut sauver la vie. Mars 2023. https:\/\/solidarites-sante.gouv.fr\/prevention-en-sante\/addictions\/article\/surdoses-overdose-d-opioides-la-naloxone-est-utilisable-par-tous-et-peut-sauver. [Consult\u00e9 le 13\u00a0juin 2023]."},{"key":"10.1016\/j.therap.2023.06.004_bib0140","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3280","article-title":"Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse","volume":"21","author":"Jouanjus","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:39:30Z","timestamp":1717220370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0040595723000847"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.06.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation des surdoses et d\u00e9c\u00e8s en lien avec la consommation de m\u00e9thadone durant la crise sanitaire li\u00e9e au COVID-19\u00a0en 2020","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}